{"filings":[{"id":787916,"accession_number":"0001193125-26-252544","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-06-02T12:00:36+00:00","items":["8.01"],"status":"ready","headline":"FDA approves Afrezza for pediatric diabetes patients ages 6+","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved supplemental BLA for Afrezza (insulin human) Inhalation Powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.","More than 350,000 U.S. children and adolescents live with diabetes; majority have type 1 and require lifelong insulin.","Approval fulfills the last postmarketing requirement from the original June 27, 2014 approval letter.","MannKind expects to expand the patient population for Afrezza beyond adults."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-06-02","daily_digest_url":"/daily/2026-06-02","daily_digest_rank":6},{"id":705640,"accession_number":"0001193125-26-243074","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-05-28T12:37:11+00:00","items":["8.01"],"status":"ready","headline":"FDA releases MannKind from Afrezza malignancy study; sBLA for children PDUFA May 29","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA informed MannKind on May 27, 2026 it is released from postmarketing requirement to assess pulmonary malignancy risk in 8,000-10,000 patients.","Only remaining postmarketing requirement for Afrezza is pediatric safety/efficacy; sBLA for ages 4-17 has PDUFA target action date May 29, 2026.","INHALE-1st study for youth (10-17) with type 1 diabetes activated eight additional sites; expects up to 100 participants across 10 sites.","Primary endpoint of INHALE-1st: percentage with CGM time in range ≥70% at 13 weeks; data expected late 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":611876,"accession_number":"0001193125-26-237183","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-05-22T21:17:49+00:00","items":["5.07"],"status":"ready","headline":"MannKind shareholders elect all 9 director nominees, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine board nominees elected; votes for ranged from 140.1M (Consiglio) to 143.5M (Binder), with 78.5M broker non-votes.","Advisory vote on executive compensation approved: 137.3M for, 16.3M against, 1.3M abstentions, 78.5M broker non-votes.","Ratification of Deloitte & Touche as auditor for FY 2026 passed: 221.1M for, 8.8M against, 3.6M abstentions, 0 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99591,"accession_number":"0001193125-26-208910","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q1 total revenue $90.2M (+15% YoY); Furoscix adds $15.5M; cash $134M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $90.2M (+15% YoY); royalties from Tyvaso DPI up 9% to $32.7M.","Furoscix net sales $15.5M (first full Q1 post-scPharma acquisition); Afrezza $15.3M (+3%).","SG&A surged 116% to $54.1M driven by launch prep for Afrezza pediatric and Furoscix ReadyFlow.","Cash and investments $134M; settled $36.3M convertible notes for $35.5M cash + 569K shares.","Key PDUFA dates: Afrezza pediatric May 29; Furoscix Autoinjector July 26; nintedanib DPI Phase 2 enrollment Q2."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":90171000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115687,"accession_number":"0001193125-26-073509","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q4 revenue $112M (+46% YoY); Furoscix adds $23M in first quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $112M in Q4 2025, up 46% vs Q4 2024; full-year revenues $349M, up 22%.","Afrezza net sales $23M in Q4, +25% YoY; Furoscix net sales $23M since acquisition Oct 7, 2025.","PDUFA target dates: Afrezza pediatric sBLA May 29, 2026; Furoscix ReadyFlow sNDA July 26, 2026.","R&D expense $27.6M (+148% YoY); SG&A $58.4M (+144%) driven by Furoscix and launch prep.","Cash & investments $176M at Dec 31, 2025; scPharmaceuticals acquisition completed Oct 7."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":348966000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132121,"accession_number":"0001193125-25-319170","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K/A","filed_at":"2025-12-15T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"MannKind pro forma shows $36.1M net loss for H1 2025 post-scPharma acquisition","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired scPharma for $5.35/share cash plus CVR (up to $1.00/share); total consideration $396.4M cash.","Pro forma combined net loss of $36.1M for six months ended June 30, 2025 vs. MannKind standalone net income of $13.8M.","Pro forma combined net loss of $96.9M for year ended Dec 31, 2024 (MannKind $27.6M income, scPharma $85.1M loss).","Acquisition financed via $325M term loan (initial $75M, DDTL $75M, incremental $175M) at SOFR + 4.75% margin.","Pro forma total assets $765.8M, total liabilities $832.6M, stockholders' deficit $66.8M as of June 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132124,"accession_number":"0001193125-25-273321","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"MannKind discontinues Phase 3 MNKD-101 trial for NTM lung disease after futility analysis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinuation based on interim analysis of first 46 participants; none showed sputum culture conversion.","DSMB agreed with decision due to futility; no safety issues identified in any DSMB meetings.","Company will investigate outcome and focus on advancing MNKD-102 dry powder formulation toward Phase 1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132123,"accession_number":"0001193125-25-265810","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q3 revenue $82.1M (+17% YoY); completes scPharma acquisition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenues $82.1M (+17% YoY); YTD revenues $237.0M (+14%).","GAAP net income $8.0M ($0.03 EPS) vs $11.6M in Q3 2024; non-GAAP net income $22.4M ($0.07) +45%.","Completed scPharmaceuticals acquisition Oct 7 with ~$133.2M cash & $250M in delayed draw term loans.","Afrezza pediatric sBLA accepted (PDUFA May 29, 2026); FUROSCIX sNDA submitted; MNKD-101 & MNKD-201 trials advancing.","Appointed Dr. Ajay Ahuja as CMO; cash & investments $286.3M at Sep 30."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":237011000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132122,"accession_number":"0001193125-25-236064","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-10-09T23:59:59+00:00","items":["1.01","2.01","2.03","9.01"],"status":"ready","headline":"MannKind completes $296.5M acquisition of scPharmaceuticals; funds with $250M debt","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer expired Oct 6 with 73.47% shares tendered; merger closed Oct 7, 2025; scPharma becomes wholly owned subsidiary.","scPharma shareholders received $5.35 cash plus one CVR per share; CVR pays up to $1.00 additional contingent on milestones.","Aggregate cash paid ~$296.5M for shares; extinguished ~$82.6M scPharma debt (Perceptive credit and revenue participation).","Funded via $250M delayed draw term loan under amended Blackstone credit facility; interest SOFR+4.75%, matures Aug 2030.","CVR Milestone 1: FDA approval of SCP-111 autoinjector by June 2027 ($0.25-$0.75); Milestone 2: net sales $110M-$120M by Dec 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148693,"accession_number":"0000950170-25-111586","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"MannKind receives $5M upfront from United Therapeutics for new product option exercise","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["MannKind entered First Amendment with United Therapeutics to exercise option for an additional development product using its Technosphere platform.","MannKind receives $5M upfront payment and is eligible for up to $35M in milestone payments.","MannKind will manufacture clinical trial materials; United Therapeutics will conduct all other preclinical and clinical development.","MannKind will earn 10% royalties on net sales of the additional product if approved.","United Therapeutics exercised withdrawal option retains right to withdraw the exercise for the new agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148692,"accession_number":"0001193125-25-186994","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"MannKind to acquire scPharmaceuticals for $5.35/share plus CVR up to $1.00/share","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Offer price: $5.35 cash + one contingent value right (CVR) per share; CVR milestones up to $1.00 aggregate.","CVR milestones: FDA approval of SCP-111 injection by June 30, 2027 (Milestone 1) and $110M+ net sales of specified products by Dec 31, 2026 (Milestone 2).","Principal stockholders holding ~11.5% of SCPH shares have agreed to tender and support the deal.","MannKind obtained $175M incremental delayed draw term loan from Blackstone to finance transaction costs; will repay ~$81M of SCPH's Perceptive debt upon close.","Strategic rationale: acquisition of FUROSCIX (approved for heart failure and chronic kidney disease) to expand into cardiorenal medicine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148691,"accession_number":"0000950170-25-103532","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q2 revenue $76.5M (+6% YoY); Afrezza sBLA for pediatric population submitted","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $76.5M, up 6% YoY; net income $0.7M versus net loss $2.0M in Q2 2024.","Afrezza sales $18.3M (+13% YoY); royalties from Tyvaso DPI $31.2M (+22%).","Non-GAAP net income $13.9M ($0.05/share) vs $14.3M ($0.05) in Q2 2024.","Submitted sBLA for Afrezza in pediatric patients (ages 4-17); FDA decision expected early Q4 2025.","ICoN-1 trial of MNKD-101 enrollment ahead of schedule; interim target of 100 patients expected early Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":154881000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167567,"accession_number":"0000950170-25-074523","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MannKind stockholders elect all 9 directors, approve say-on-pay, ratify auditor at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected 9 directors (including James S. Shannon, Michael E. Castagna) with between 133.7M and 137.8M votes for each.","Advisory vote on named executive officer compensation approved: 131.4M for, 11.5M against.","Ratified Deloitte & Touche as auditor for FY2025: 211.7M for, 5.3M against, no broker non-votes.","Broker non-votes were 75.7M on director elections and say-on-pay, but 0 on auditor ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167566,"accession_number":"0001193125-25-120797","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"MannKind Chief Medical Officer Burkhard Blank to depart; separation terms include $386K bonus","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Burkhard Blank stepped down as CMO and EVP R&D effective May 9, 2025, becoming non-executive employee.","Last day of employment is August 1, 2025; base salary continued for 13 weeks through Oct 31, 2025.","One-time special bonus of $386,000 payable in January 2026; COBRA premiums reimbursed until Oct 31.","Equity awards continue to vest while Blank remains employed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167565,"accession_number":"0000950170-25-066426","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q1 revenue $78M (+18% YoY); net income $13.2M (+24%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["1Q25 revenue $78.4M (+18% YoY); GAAP net income $13.2M (+24%); non-GAAP net income $21.6M (+43%).","Royalty revenue $30M (+32%) from increased Tyvaso DPI demand; collaborations & services $29.4M (+18%) from United Therapeutics.","Afrezza NRx grew 20% YoY; sBLA for pediatric approval expected mid-2025.","MNKD-101 Phase 3 ICON-1: 55 patients randomized, 85% sites activated; target 100 patients by YE 2025.","Cash & investments $198M; MNKD-201 (nintedanib DPI) expected to advance to next phase in 2H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":78354000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184854,"accession_number":"0000950170-25-027721","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind reports 2024 revenue of $286M, net income of $28M; debt reduced by $236M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 revenue $286M (+43% YoY); Q4 revenue $77M (+31% YoY).","GAAP net income $27.6M ($0.10 EPS basic) vs loss of $11.9M in 2023; non-GAAP net income $67.7M ($0.25 EPS).","Reduced debt principal by $236M, remaining $36M convertible notes; year-end cash $203M.","Afrezza INHALE-1 pediatric trial met primary endpoint; FDA meeting planned 1H 2025 for potential sNDA.","MNKD-101 Phase 3 interim enrollment target expected by YE 2025; MNKD-201 Phase 1 completed."],"consensus_eps_estimate":null,"consensus_eps_actual":0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":285504000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184853,"accession_number":"0000950170-25-002291","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Lauren Sabella to retire from MannKind July 18, 2025; appointed EVP, Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lauren Sabella notified retirement effective July 18, 2025.","Board appointed Sabella as Executive Vice President, Operations effective January 6, 2025.","Sabella remains on executive leadership team until retirement but will no longer oversee Endocrine Business Unit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201447,"accession_number":"0001193125-24-280821","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"MannKind exchanges $193.7M of 2.50% convertible notes for 26.7M shares plus $89.2M cash","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $193.7M of 2.50% Convertible Senior Notes due 2026 exchanged for 26,749,559 shares of common stock.","Cash payment of ~$89.2M additional exchange consideration.","Closings expected on Dec. 20 and Dec. 23, 2024, subject to conditions.","After exchange, ~$36.3M principal of Notes remains outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201446,"accession_number":"0000950170-24-123273","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q3 total revenue $70M (+37% YoY); YTD net income $20M, non-GAAP $45M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 total revenue $70.1M (+37% YoY); YTD revenue $208.7M (+49% YoY); YTD net income $20M.","Tyvaso DPI royalties up 34% to $27.1M (Q3) and 48% YTD to $75.3M; collaboration revenue +78% on manufacturing.","Afrezza net revenue up 12% to $15.0M (Q3); V-Go net revenue up 5% to $4.7M.","Pipeline: MNKD-101 Phase 3 global expansion; MNKD-201 Phase 1 complete, FDA meeting 1H 2025; INHALE-3 positive; pediatric data due Q4.","Cash and investments $268.4M; $5.3M bargain purchase gain from Pulmatrix deal."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":208728000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217450,"accession_number":"0001193125-24-200252","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kent Kresa to retire from MannKind Board; Steven B. Binder appointed effective Sept 30, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kent Kresa notified MannKind board of his retirement on Aug 13, effective Sept 30, 2024.","Board approved appointment of Steven B. Binder as director, effective on Kresa's retirement date.","Binder currently serves as EVP, Special Projects; his employment will end concurrently with board appointment.","Binder will be eligible for non-employee director compensation as described in prior SEC filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217449,"accession_number":"0000950170-24-092289","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q2 revenue $72M (+49% YoY), net income $9M YTD; pipeline advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 total revenues $72.4M, up 49% vs. $48.6M in Q2 2023; YTD revenues $138.6M, up 55%.","YTD 2024 net income of $9M; non-GAAP net income $29M; cash & investments $261.9M.","Tyvaso DPI royalties up 34% to $25.6M; collaborations and services revenue up 132% to $26.0M.","Afrezza net revenue $16.3M (+20%); V-Go net revenue $4.5M (-7%).","Pipeline: MNKD-101 Phase 3 initiated; MNKD-201 Phase 1 on track for 4Q 2024 readout."],"consensus_eps_estimate":null,"consensus_eps_actual":0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":138649000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237317,"accession_number":"0000950170-24-061164","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"MannKind shareholders elect all nine directors, approve say-on-pay, ratify Deloitte","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Nine director nominees elected; highest votes 120.0M for Sabrina Kay, lowest 118.5M for Ronald Consiglio.","Advisory vote on executive compensation approved: 112.3M for, 11.6M against, 72.3M broker non-votes.","Ratification of Deloitte & Touche as auditor passed: 191.8M for, 3.8M against, 0 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237316,"accession_number":"0000950170-24-055622","cik":899460,"company_name":"MANNKIND CORP","ticker":"MNKD","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"MannKind Q1 revenue $66M (+63% YoY); net income $11M; FDA Fast Track for MNKD-101","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $66.3M (+63% YoY); GAAP net income $11M; non-GAAP net income $15M.","Tyvaso DPI royalties surged 94% to $22.7M; collaborations & services revenue up 118% to $24.8M.","Afrezza net revenue $14.4M (+16%); V-Go down 16% to $4.3M.","Cash and investments $304.5M; repaid ~$37M of secured debt in early April.","FDA Fast Track and IND clearance for MNKD-101 (clofazimine inhaled suspension)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":66263000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1096773076.246459,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}